HUE064609T2 - Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok - Google Patents

Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok

Info

Publication number
HUE064609T2
HUE064609T2 HUE20150584A HUE20150584A HUE064609T2 HU E064609 T2 HUE064609 T2 HU E064609T2 HU E20150584 A HUE20150584 A HU E20150584A HU E20150584 A HUE20150584 A HU E20150584A HU E064609 T2 HUE064609 T2 HU E064609T2
Authority
HU
Hungary
Prior art keywords
tetrahydronaphthalene
estrogen receptor
tetrahydroisoquinoline derivatives
receptor degraders
degraders
Prior art date
Application number
HUE20150584A
Other languages
English (en)
Inventor
Andrew P Crew
Yimin Qian
Hanqing Dong
Jing Wang
Keith R Hornberger
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of HUE064609T2 publication Critical patent/HUE064609T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE20150584A 2016-12-01 2017-12-01 Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok HUE064609T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662429041P 2016-12-01 2016-12-01
US201762540049P 2017-08-01 2017-08-01

Publications (1)

Publication Number Publication Date
HUE064609T2 true HUE064609T2 (hu) 2024-04-28

Family

ID=62240410

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE20150584A HUE064609T2 (hu) 2016-12-01 2017-12-01 Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok

Country Status (23)

Country Link
US (6) US10647698B2 (hu)
EP (2) EP3548483A4 (hu)
JP (5) JP6957620B2 (hu)
KR (3) KR102674902B1 (hu)
CN (3) CN110291087B (hu)
AU (5) AU2017366693B2 (hu)
BR (1) BR112019011200B1 (hu)
CA (1) CA3042968C (hu)
CO (1) CO2019007091A2 (hu)
DK (1) DK3689868T3 (hu)
ES (1) ES2967404T3 (hu)
FI (1) FI3689868T3 (hu)
HR (1) HRP20231537T1 (hu)
HU (1) HUE064609T2 (hu)
IL (4) IL266842B (hu)
LT (1) LT3689868T (hu)
MX (2) MX2019006402A (hu)
PL (1) PL3689868T3 (hu)
PT (1) PT3689868T (hu)
RS (1) RS64976B1 (hu)
RU (1) RU2750484C2 (hu)
SI (1) SI3689868T1 (hu)
WO (1) WO2018102725A1 (hu)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
US10683387B2 (en) 2016-10-04 2020-06-16 Massachusetts Institute Of Technology Bottlebrush copolymers and uses thereof
AU2017367872B2 (en) 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
RU2750484C2 (ru) 2016-12-01 2021-06-28 Эрвинэс Оперейшнс, Инк. Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119448A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
CN111278815B (zh) 2017-09-04 2024-03-08 C4医药公司 戊二酰亚胺
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
KR20230130752A (ko) 2018-04-04 2023-09-12 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
IL302595A (en) * 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
DK3784663T3 (da) 2018-04-23 2023-10-16 Celgene Corp Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN113164409B (zh) * 2018-11-21 2023-07-18 冰洲石生物科技公司 具有雌激素受体α降解活性的化合物及其用途
US20240245670A1 (en) * 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2022515890A (ja) * 2019-01-03 2022-02-22 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン エストロゲン受容体タンパク質分解薬
BR112021015672A2 (pt) * 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113747925A (zh) 2019-03-21 2021-12-03 科迪亚克生物科学公司 胞外囊泡缀合物及其用途
WO2020191369A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
TW202102497A (zh) 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
US20220241424A1 (en) 2019-04-16 2022-08-04 Northwestern University Treatment of cancer
US20220220124A1 (en) * 2019-04-18 2022-07-14 Accutar Biotechnology Inc. Novel compounds having bet, estrogen receptor, and androgen receptor degradation activity and uses thereof
CN114867727A (zh) 2019-07-17 2022-08-05 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
WO2021018118A1 (en) * 2019-07-29 2021-02-04 Janssen Pharmaceutica Nv Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
JP2022546471A (ja) 2019-08-26 2022-11-04 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
JP7307796B2 (ja) * 2019-09-23 2023-07-12 アキュター バイオテクノロジー インコーポレイテッド アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
CN112574278B (zh) * 2019-09-29 2024-08-23 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
TWI836159B (zh) 2019-11-19 2024-03-21 美商必治妥美雅史谷比公司 可作為helios蛋白質抑制劑之化合物
EP4069228A4 (en) * 2019-12-06 2024-04-17 Celgene Corporation PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE
DK3835298T3 (da) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Nye chromanderivater med østrogenreceptornedbrydende aktivitet og anvendelser heraf
EP4076464A4 (en) * 2019-12-17 2024-06-12 Orionis Biosciences, Inc. COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION
BR112022011796A2 (pt) 2019-12-18 2022-08-30 Novartis Ag Derivados de 3-(5-metóxi-1- oxoisoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
MX2022007678A (es) 2019-12-19 2022-09-19 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
JP2023508357A (ja) * 2019-12-23 2023-03-02 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
US12042513B2 (en) * 2020-01-10 2024-07-23 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof
JP2023512040A (ja) * 2020-01-29 2023-03-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
WO2021170021A1 (zh) * 2020-02-25 2021-09-02 上海科技大学 基于戊二酰亚胺骨架的化合物及其应用
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
CN111393409A (zh) * 2020-03-27 2020-07-10 苏州昊帆生物股份有限公司 蛋白降解靶向嵌合体化合物、应用及其制备方法
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
PE20231555A1 (es) * 2020-09-14 2023-10-03 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos
CN112094275A (zh) * 2020-09-16 2020-12-18 迪嘉药业集团有限公司 一种（右）佐匹克隆光降解杂质的制备方法
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
IL302669A (en) 2020-11-06 2023-07-01 Prelude Therapeutics Inc BRM-targeted compounds and related methods of use
KR20230121801A (ko) * 2020-12-14 2023-08-21 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌유도체로 유방암을 치료하는 방법
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
CN116438177A (zh) * 2021-01-28 2023-07-14 江苏亚虹医药科技股份有限公司 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
EP4289841A1 (en) * 2021-02-04 2023-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
CA3211378A1 (en) * 2021-03-29 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
IL307338A (en) 2021-04-05 2023-11-01 Bristol Myers Squibb Co Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
JP2024515243A (ja) 2021-04-06 2024-04-08 ブリストル－マイヤーズ スクイブ カンパニー ピリジニル置換されたオキソイソインドリン化合物
AU2022259683A1 (en) 2021-04-16 2023-10-19 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
EP4334302A1 (en) * 2021-05-03 2024-03-13 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
US20240287076A1 (en) 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
AR126052A1 (es) * 2021-06-03 2023-09-06 Novartis Ag Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
EP4367113A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
EP4366834A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
CN117715889A (zh) 2021-07-26 2024-03-15 阿尔维纳斯运营股份有限公司 制备双官能化合物的方法
EP4421071A1 (en) * 2021-10-22 2024-08-28 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
CA3237756A1 (en) 2021-11-09 2023-05-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Wee1 protein kinase degradation agent and use thereof
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2023242598A1 (en) * 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
WO2024006776A1 (en) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
TW202417425A (zh) * 2022-06-27 2024-05-01 美商傳達治療有限公司 雌激素受體α降解劑及其使用方法
US20240067632A1 (en) * 2022-06-30 2024-02-29 Bristol-Myers Squibb Company WEE1 Degrading Compounds and Uses Thereof
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
TW202416992A (zh) 2022-08-31 2024-05-01 美商亞文納營運公司 雌激素受體降解劑之給藥方案
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
US20240158370A1 (en) * 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024067781A1 (zh) * 2022-09-29 2024-04-04 江苏恒瑞医药股份有限公司 一种四氢萘类衍生物的可药用盐、晶型及制备方法
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
KR20240078553A (ko) * 2022-11-25 2024-06-04 재단법인 대구경북첨단의료산업진흥재단 선택적 에스트로겐 수용체 조절제로서의 신규 화합물
WO2024119081A1 (en) 2022-12-02 2024-06-06 Arvinas Operations, Inc. Method of treating breast cancer
CN116751186A (zh) * 2022-12-23 2023-09-15 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
CN118556048A (zh) * 2022-12-27 2024-08-27 标新生物医药科技(上海)有限公司 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用
WO2024141052A1 (zh) * 2022-12-30 2024-07-04 江苏威凯尔医药科技有限公司 雌激素受体调节剂及其用途
WO2024167904A1 (en) 2023-02-07 2024-08-15 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
CA2624949C (en) 1996-07-24 2011-02-15 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
CA2287387C (en) 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
WO1999015521A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Benzothiophenes
ES2220005T3 (es) * 1998-06-16 2004-12-01 Pfizer Products Inc. Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
AU769652B2 (en) 1999-05-05 2004-01-29 Cubist Pharmaceuticals, Inc. Novel prolines as antimicrobial agents
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
EP1322750A4 (en) 2000-09-08 2004-09-29 California Inst Of Techn PROTEOLYSIC CHIMERAL PHARMACEUTICAL
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CN1264858C (zh) 2001-02-16 2006-07-19 纳幕尔杜邦公司 血管生成抑制三肽、组合物及其使用方法
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
EP1735307B1 (en) 2004-04-07 2012-08-29 Novartis AG Inhibitors of iap
RU2401840C2 (ru) 2004-07-02 2010-10-20 Дженентек, Инк. Ингибиторы iap
US20060167066A1 (en) 2004-12-20 2006-07-27 Genentech, Inc. Pyrrolidine inhibitors of IAP
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
AU2006216450C1 (en) 2005-02-25 2013-01-10 Medivir Ab Dimeric IAP inhibitors
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
US20060252698A1 (en) 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
MX2008002765A (es) 2005-08-31 2008-04-07 Celgene Corp Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
MX2008011128A (es) 2006-03-03 2008-09-08 Novartis Ag Compuestos de n-formil-hidroxilamina.
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0711326B8 (pt) 2006-05-05 2021-05-25 Univ Michigan Regents compostos miméticos de smac bivalentes
AU2007275415A1 (en) 2006-07-20 2008-01-24 Ligand Pharmaceuticals Incorporated Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2057143B1 (en) 2006-08-30 2013-07-24 Celgene Corporation 5-substituted isoindoline compounds
RU2448101C2 (ru) 2006-08-30 2012-04-20 Селджин Корпорейшн 5-замещенные изоиндолиновые соединения
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2008109057A1 (en) 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
BRPI0810178A2 (pt) 2007-04-12 2014-09-23 Joyant Pharmaceuticals Inc Dímeros e trímeros miméticos de smac úteis como agentes anticâncer
JP5416089B2 (ja) 2007-04-13 2014-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ジアゾ二環式ｓｍａｃ模倣物およびその使用
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
US20100203012A1 (en) 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
KR20100032886A (ko) * 2007-06-08 2010-03-26 아보트 러보러터리즈 키나제 억제제로서의 5-헤테로아릴 치환된 인다졸
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US8063102B2 (en) * 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CN102958928B (zh) 2009-10-28 2015-05-13 焦阳特制药股份有限公司 二聚体smac模拟物
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
NZ601289A (en) 2010-02-11 2014-10-31 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012003281A2 (en) 2010-06-30 2012-01-05 Brandeis University Small-molecule-targeted protein degradation
CA2811567C (en) 2010-09-24 2019-09-10 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
CN102477033A (zh) 2010-11-23 2012-05-30 苏州波锐生物医药科技有限公司 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
CN102477017A (zh) * 2010-11-23 2012-05-30 苏州波锐生物医药科技有限公司 四氢萘衍生物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
WO2012090104A1 (en) 2010-12-31 2012-07-05 Kareus Therapeutics, Sa Methods and compositions for designing novel conjugate therapeutics
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
WO2013071039A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
EP2776409B1 (en) 2011-11-09 2016-02-03 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
CN103159736B (zh) 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
DK2797888T3 (en) 2011-12-31 2016-09-19 Beigene Ltd Fused tricyclic compounds as RAF kinase inhibitors
RU2666530C2 (ru) * 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2846784A4 (en) 2012-05-11 2016-03-09 Univ Yale COMPOUNDS USEFUL FOR STIMULATING PROTEIN DEGRADATION AND METHODS USING THE SAME
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
JP6067108B2 (ja) 2012-05-30 2017-01-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 置換ピロリジン−２−カルボキサミド
US9345740B2 (en) 2012-07-10 2016-05-24 Bristol-Myers Squibb Company IAP antagonists
PL2880447T3 (pl) 2012-07-31 2019-10-31 Novartis Ag Markery związane z wrażliwością na inhibitory ludzkiego białka „double minute " 2 (mdm2)
WO2014025759A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
EP2903998B1 (en) 2012-10-02 2017-03-15 Bristol-Myers Squibb Company Iap antagonists
CA2930030A1 (en) 2012-11-09 2014-05-15 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014100071A2 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted pyrrolopyrimidines as hdm2 inhibitors
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
NL2011274C2 (en) 2013-08-06 2015-02-09 Illumicare Ip B V 51 Groundbreaking platform technology for specific binding to necrotic cells.
CN105121407B (zh) 2013-02-28 2017-07-18 美国安进公司 用于治疗癌症的苯甲酸衍生物mdm2抑制剂
MX2015012427A (es) 2013-03-14 2016-01-12 Amgen Inc Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US9637518B2 (en) 2013-07-12 2017-05-02 Bristol-Myers Squibb Company IAP antagonists
JP2017507964A (ja) * 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
MX2016013563A (es) 2014-04-14 2017-05-09 Arvinas Inc Moduladores de la proteolisis basados en imida y metodos de uso asociados.
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
MX2017004246A (es) * 2014-10-03 2017-05-19 Conagen Inc Edulcorantes no caloricos y metodos para sintetizar.
US9845291B2 (en) * 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED PROTEASE MODULATORS AND METHODS OF USE THEREOF
WO2017011590A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP3331905B1 (en) 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
EP3429996A4 (en) 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES DIRECTED AGAINST CEREBLON TO IMPROVE THE FUNCTION OF T EFFECTOR LYMPHOCYTES
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
WO2017185036A1 (en) 2016-04-22 2017-10-26 Dana Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
JP7009466B2 (ja) * 2016-10-11 2022-02-10 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体の標的分解のための化合物および方法
AU2017367872B2 (en) 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
RU2750484C2 (ru) 2016-12-01 2021-06-28 Эрвинэс Оперейшнс, Инк. Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
WO2018119448A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP2022546471A (ja) 2019-08-26 2022-11-04 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
DK3835298T3 (da) 2019-12-12 2024-07-29 Accutar Biotechnology Inc Nye chromanderivater med østrogenreceptornedbrydende aktivitet og anvendelser heraf
CN113816927B (zh) 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法

Also Published As

Publication number Publication date
US11104666B2 (en) 2021-08-31
KR102674902B1 (ko) 2024-06-14
AU2021257895A1 (en) 2021-11-18
RU2019120120A (ru) 2020-12-28
JP2020504089A (ja) 2020-02-06
RU2750484C2 (ru) 2021-06-28
EP3548483A1 (en) 2019-10-09
JP7160497B2 (ja) 2022-10-25
AU2020201793B2 (en) 2020-08-27
JP2023021211A (ja) 2023-02-10
FI3689868T3 (fi) 2023-12-18
RS64976B1 (sr) 2024-01-31
KR102173464B9 (ko) 2022-05-23
KR20190082989A (ko) 2019-07-10
AU2017366693A9 (en) 2019-05-02
JP6957620B2 (ja) 2021-11-02
KR20240063185A (ko) 2024-05-10
AU2017366693B2 (en) 2021-04-01
RU2019120120A3 (hu) 2021-03-24
AU2024201437A1 (en) 2024-03-21
IL284424A (en) 2021-07-29
ES2967404T3 (es) 2024-04-30
KR102173464B1 (ko) 2020-11-04
CA3042968A1 (en) 2018-06-07
AU2021204549B2 (en) 2023-07-06
IL284424B2 (en) 2023-04-01
PT3689868T (pt) 2024-01-02
IL272527A (en) 2020-03-31
RU2020106142A (ru) 2020-04-13
RU2020106142A3 (hu) 2020-08-07
AU2017366693A1 (en) 2019-04-18
EP3689868A1 (en) 2020-08-05
IL284424B (en) 2022-12-01
US10647698B2 (en) 2020-05-12
IL266842A (en) 2019-07-31
MX2022010583A (es) 2022-12-13
CN114656452B (zh) 2023-01-17
SI3689868T1 (sl) 2024-02-29
CN110291087A (zh) 2019-09-27
EP3689868B1 (en) 2023-09-27
BR112019011200A2 (pt) 2019-10-08
US20180155322A1 (en) 2018-06-07
EP3548483A4 (en) 2020-06-10
US11597720B2 (en) 2023-03-07
IL272527B (en) 2021-07-29
LT3689868T (lt) 2023-12-27
DK3689868T3 (da) 2024-01-02
WO2018102725A1 (en) 2018-06-07
MX2019006402A (es) 2019-09-11
US20240076281A1 (en) 2024-03-07
BR112019011200B1 (pt) 2021-12-28
PL3689868T3 (pl) 2024-03-11
US20220388984A1 (en) 2022-12-08
JP2021169479A (ja) 2021-10-28
IL266842B (en) 2022-09-01
US10899742B1 (en) 2021-01-26
KR20200020988A (ko) 2020-02-26
CO2019007091A2 (es) 2019-10-09
HRP20231537T1 (hr) 2024-03-15
JP6972211B2 (ja) 2021-11-24
AU2020201793A1 (en) 2020-03-26
JP2022023103A (ja) 2022-02-07
CN110291087B (zh) 2024-07-09
US20220274955A1 (en) 2022-09-01
CN111454248A (zh) 2020-07-28
JP2020100659A (ja) 2020-07-02
CA3042968C (en) 2023-10-17
CN114656452A (zh) 2022-06-24
US20210139458A1 (en) 2021-05-13
AU2021204549A1 (en) 2021-08-05
IL297717A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
IL284424B (en) History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
ZA201805573B (en) Selective estrogen receptor degraders and uses thereof
HK1247199A1 (zh) 雌激素受體調節劑及其用途
IL266353A (en) Steroids and their protein conjugates
IL285318A (en) Estrogen receptor modulators
HK1248683A1 (zh) 雜環雌激素受體調節劑及其用途
HK1258851A1 (zh) 四氫萘雌激素受體調節劑及其用途
IL247252B (en) History of isoquinoline and its use
HK1258886A1 (zh) T細胞受體及其用途
HK1252202A1 (zh) 部署裝置及相關的組件和方法
ZA201900113B (en) Ethynyl derivatives
GB2546327B (en) Security cowl and fixing
HK1253294A1 (zh) 阿片受體調節劑及其用途
IL261055B (en) Tetrahydroisoquinoline derivatives
GB2550927B (en) Repositionable self-adhesive closed-cell solid-foam insulation material
GB201500597D0 (en) DAP wallpaper (Design and Print Wallpaper)